Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Brahmer, J.; Tykodi, S.; Chow, L.; Hwu, W.; Topalian, S.; Hwu, P.; Drake, C.; Camacho, L.; Kauh, J.; Odunsi, K.; Pitot, H.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, Shuming; M Salay, Theresa; Alaparthy, S.; Grosso, J.; Korman, A.; Parker, S.; Agrawal, S.; M. Goldberg, S.; Pardoll, D.; Gupta, A.; Wigginton, J.

doi:10.1056/NEJMoa1200694

Public

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Shared by NobleBlocks on Jun 2, 2012 • 12:00 AM UTC

Authors:

J. Brahmer

S. Tykodi

L. Chow

Abstract

BACKGROUND Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host’s immune system. Blockade of interactions between PD-1 and PD-L1 enhances immune function in vitro and mediates antitumor a...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!